Security Snapshot

SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) Institutional Ownership

CUSIP: 78397T202

13F Institutional Holders and Ownership History from Q4 2023 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

71

Shares (Excl. Options)

69.72MFull value: 69,718,713 · shares · 30 Sep 2026

Price

$3.17

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+9,033,343
Value change
+$28,604,361
Number of holders
71
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
95,713,930
SEC-reported price per share
$3.23
Insider filing price
$3.23
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 78397T202.
  • 71 institutions reported positions in Q3 2026.
  • 11 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 88 to 71 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $266.75MFull value: $266,753,897 · USD · 30 Jun 2026
    to
    $221.01MFull value: $221,008,745 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 71 institutions filings for Q3 2026.

Open SEC evidence

Security key

78397T202

13F reference period

Q3 2026

13F holders

71

13D/G owners

11

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
11
Security
SABS
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Vivo Opportunity Fund Holdings, L.P. 10% 0% $70,651,378 -$1,108,254 22,287,501 -1.5% Vivo Opportunity Fund Holdings, L.P. 30 Sep 2026
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $38,055,014 +$9,102,563 9,609,852 +31% RA Capital Management, L.P. 06 Aug 2026
Commodore Capital LP 9.9% 0% $35,434,753 +$17,523,764 8,948,170 +98% Commodore Capital LP 30 Jun 2026
Caligan Partners LP 8.8% -16% $31,550,140 7,967,207 0% Caligan Partners LP 30 Jun 2026
BALYASNY ASSET MANAGEMENT L.P. 7.9% -17% $22,904,642 7,225,439 0% BALYASNY ASSET MANAGEMENT L.P. 30 Sep 2026
PERCEPTIVE ADVISORS LLC 7.3% -14% $26,244,904 +$775,202 6,627,501 +3% Perceptive Advisors LLC 30 Jun 2026
Adage Capital Management, L.P. 8.4% $25,365,990 6,405,553 Adage Capital Management, L.P. 30 Jun 2026
Woodline Partners LP 5.7% -16% $17,294,550 +$1,075 5,455,694 +0.01% Woodline Partners LP 30 Sep 2026
BIOTECHNOLOGY VALUE FUND L P 9.1% -8.9% $18,761,910 -$1,598,505 4,761,906 -7.9% BVF PARTNERS L P/IL 31 Dec 2025
MILLENNIUM MANAGEMENT LLC 5.1% $13,385,397 3,432,153 Millennium Management LLC 24 Apr 2026
RTW INVESTMENTS, LP 3.2% -68% $6,253,970 +$2,218,090 1,587,302 +55% RTW Investments, LP 31 Dec 2025
As of 30 Sep 2026, 71 institutional investors reported holding
69.72MFull value: 69,718,713 · shares · 30 Sep 2026
shares of SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS). This represents 73% of the company’s total
95.71MFull value: 95,713,930 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
63%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Caligan Partners LP 9.1% 8,736,898 1.7% $27,695,967
Vivo Capital, LLC 7.2% 6,915,011 2.4% $21,920,585
PERCEPTIVE ADVISORS LLC 6.9% 6,627,501 0.39% $21,009,178
ADAGE CAPITAL PARTNERS GP, L.L.C. 6.7% 6,405,553 0.03% $20,305,603
RA CAPITAL MANAGEMENT, L.P. 4.6% 4,401,500 0.14% $13,952,755
VANGUARD CAPITAL MANAGEMENT LLC 3.2% 3,088,536 0% $9,790,659
Commodore Capital LP 3% 2,870,000 0.7% $9,097,900
Boxer Capital Management, LLC 2.6% 2,500,000 0.69% $7,925,000
Spruce Street Capital LP 2.3% 2,198,502 1.1% $6,969,251
Sanofi 2.3% 2,198,500 1.1% $6,969,245
Sessa Capital IM, L.P. 2.3% 2,198,457 0.11% $6,969,109
Blackstone Inc. 2.1% 2,051,633 0.02% $6,503,677
Affinity Asset Advisors, LLC 1.6% 1,525,000 0.27% $4,834,250
GEODE CAPITAL MANAGEMENT, LLC 1.4% 1,376,387 0% $4,364,082
Propel Bio Management, LLC 1.2% 1,187,422 2.1% $3,764,128
Woodline Partners LP 1.2% 1,180,694 0.01% $3,742,800
Seven Fleet Capital Management LP 0.79% 752,772 0.47% $2,386,287
STATE STREET CORP 0.77% 737,138 0% $2,336,727
Soleus Capital Management, L.P. 0.7% 672,039 0.08% $2,130,364
ExodusPoint Capital Management, LP 0.63% 600,193 0.01% $1,902,612
VANGUARD FIDUCIARY TRUST CO 0.44% 422,015 0% $1,337,788
Polymer Capital Management (HK) LTD 0.44% 416,564 0.13% $1,320,508
DV EQUITIES, LLC 0.42% 400,000 0.25% $1,268,000
AWM Investment Company, Inc. 0.39% 375,000 0.11% $1,188,750
VANGUARD PORTFOLIO MANAGEMENT LLC 0.39% 372,890 0% $1,182,061

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
12
Headline period
Q3 2026
Rows shown
1-12 of 12
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 69,718,713 $221,008,745 +$28,604,361 $3.17 71
2026 Q2 68,398,247 $266,753,897 -$2,809,173 $3.90 88
2026 Q1 69,191,893 $265,013,025 +$122,542,646 $3.83 75
2025 Q4 36,342,111 $135,919,535 +$25,718,819 $3.74 48
2025 Q3 28,023,938 $56,328,113 +$52,469,483 $2.01 34
2025 Q2 1,923,874 $3,369,565 -$378,633 $1.76 25
2025 Q1 2,209,552 $2,994,479 -$1,776,863 $1.36 26
2024 Q4 2,652,300 $10,189,778 -$1,266,185 $3.79 26
2024 Q3 3,141,736 $8,482,377 +$68,507 $2.70 24
2024 Q2 3,127,151 $9,694,108 -$923,501 $3.10 21
2024 Q1 3,339,666 $15,162,138 -$15,603,353 $4.54 23
2023 Q4 8,791,109 $6,055,351 +$6,055,351 $0.69 3
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .